MicuRx Pharmaceuticals, Inc., a Hayward, CA-based biopharmaceutical company developing innovative antibiotics, raised $25m in Series B financing.
The round was led by BVCF, with participation from existing investors Morningside Group and Devon Park Bioventures. In conjunction with the funding, Weixin Xu and Davis Yang of BVCF will join the company’s board of directors.
Led by Zhengyu Yuan, Ph.D., president and chief executive officer, MicuRx Pharmaceuticals is developing novel antibiotics to combat infections due to resistant bacteria.
The company intends to use the capital to fund the U.S. development of MRX-I, a novel oral oxazolidinone antibiotic targeting infections due to multi-drug resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
MicuRx also has research and development facilities in Hayward, CA and Shanghai, China.
To date, it has raised $37m in funding.